Oral Pemphigoid Recalcitrant Lesion Treated with PRGF Infiltration. Case Report

Mucous membrane pemphigoid (MMP) is a heterogeneous group of chronic autoimmune subepithelial blistering diseases. Oral involvement is present in almost all patients, may represent the onset of the disease, and causes different degrees of pain, dysphagia, soreness, and bleeding. Treatment is based o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eduardo Anitua, Mohammad H. Alkhraisat, Asier Eguia, Laura Piñas
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	benign mucous membrane pemphigoid autoimmune disease vesiculobullous dermatoses platelet rich plasma case report Dentistry RK1-715
Acceso en línea:	https://doaj.org/article/a98b6003c7d2483594fad02a3bd98bb4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a98b6003c7d2483594fad02a3bd98bb4
record_format	dspace
spelling	oai:doaj.org-article:a98b6003c7d2483594fad02a3bd98bb42021-11-25T17:20:02ZOral Pemphigoid Recalcitrant Lesion Treated with PRGF Infiltration. Case Report10.3390/dj91101372304-6767https://doaj.org/article/a98b6003c7d2483594fad02a3bd98bb42021-11-01T00:00:00Zhttps://www.mdpi.com/2304-6767/9/11/137https://doaj.org/toc/2304-6767Mucous membrane pemphigoid (MMP) is a heterogeneous group of chronic autoimmune subepithelial blistering diseases. Oral involvement is present in almost all patients, may represent the onset of the disease, and causes different degrees of pain, dysphagia, soreness, and bleeding. Treatment is based on systemic and/or oral corticoids, or other immunosuppressants. Occasionally, oral lesions can show a poor response to standard treatments. We present the case of a 61-year-old female patient with a painful extensive MMP oral ulcerative lesion recalcitrant to previous systemic azathioprine and local triamcinolone treatment, which was successfully treated in a novel way using PRGF infiltrations as adjuvant. After four weekly infiltrations, pain was reduced from 10 to 0 in a VAS and the lesion was completely healed. The patient continued with a low dose maintenance immunosuppressive treatment (prednisone 5 mg/day PO), and after 13 months of follow-up, there was no relapse of the lesion and no side effects. Although future research is necessary to confirm these observations, PRGF could be a useful adjuvant for the management of extensive mucous membrane pemphigoid oral lesions.Eduardo AnituaMohammad H. AlkhraisatAsier EguiaLaura PiñasMDPI AGarticlebenign mucous membrane pemphigoidautoimmune diseasevesiculobullous dermatosesplatelet rich plasmacase reportDentistryRK1-715ENDentistry Journal, Vol 9, Iss 137, p 137 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	benign mucous membrane pemphigoid autoimmune disease vesiculobullous dermatoses platelet rich plasma case report Dentistry RK1-715
spellingShingle	benign mucous membrane pemphigoid autoimmune disease vesiculobullous dermatoses platelet rich plasma case report Dentistry RK1-715 Eduardo Anitua Mohammad H. Alkhraisat Asier Eguia Laura Piñas Oral Pemphigoid Recalcitrant Lesion Treated with PRGF Infiltration. Case Report
description	Mucous membrane pemphigoid (MMP) is a heterogeneous group of chronic autoimmune subepithelial blistering diseases. Oral involvement is present in almost all patients, may represent the onset of the disease, and causes different degrees of pain, dysphagia, soreness, and bleeding. Treatment is based on systemic and/or oral corticoids, or other immunosuppressants. Occasionally, oral lesions can show a poor response to standard treatments. We present the case of a 61-year-old female patient with a painful extensive MMP oral ulcerative lesion recalcitrant to previous systemic azathioprine and local triamcinolone treatment, which was successfully treated in a novel way using PRGF infiltrations as adjuvant. After four weekly infiltrations, pain was reduced from 10 to 0 in a VAS and the lesion was completely healed. The patient continued with a low dose maintenance immunosuppressive treatment (prednisone 5 mg/day PO), and after 13 months of follow-up, there was no relapse of the lesion and no side effects. Although future research is necessary to confirm these observations, PRGF could be a useful adjuvant for the management of extensive mucous membrane pemphigoid oral lesions.
format	article
author	Eduardo Anitua Mohammad H. Alkhraisat Asier Eguia Laura Piñas
author_facet	Eduardo Anitua Mohammad H. Alkhraisat Asier Eguia Laura Piñas
author_sort	Eduardo Anitua
title	Oral Pemphigoid Recalcitrant Lesion Treated with PRGF Infiltration. Case Report
title_short	Oral Pemphigoid Recalcitrant Lesion Treated with PRGF Infiltration. Case Report
title_full	Oral Pemphigoid Recalcitrant Lesion Treated with PRGF Infiltration. Case Report
title_fullStr	Oral Pemphigoid Recalcitrant Lesion Treated with PRGF Infiltration. Case Report
title_full_unstemmed	Oral Pemphigoid Recalcitrant Lesion Treated with PRGF Infiltration. Case Report
title_sort	oral pemphigoid recalcitrant lesion treated with prgf infiltration. case report
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a98b6003c7d2483594fad02a3bd98bb4
work_keys_str_mv	AT eduardoanitua oralpemphigoidrecalcitrantlesiontreatedwithprgfinfiltrationcasereport AT mohammadhalkhraisat oralpemphigoidrecalcitrantlesiontreatedwithprgfinfiltrationcasereport AT asiereguia oralpemphigoidrecalcitrantlesiontreatedwithprgfinfiltrationcasereport AT laurapinas oralpemphigoidrecalcitrantlesiontreatedwithprgfinfiltrationcasereport
_version_	1718412489263153152

Oral Pemphigoid Recalcitrant Lesion Treated with PRGF Infiltration. Case Report

Ejemplares similares